Life-supporting Kidney Xenotransplantation From Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 10 7 2019
medline: 20 6 2020
entrez: 9 7 2019
Statut: ppublish

Résumé

The aims of this study were to evaluate the efficacy of US Food and Drug Administration-approved drugs in genetically engineered pig-to-baboon kidney xenotransplantation and compare the results with those using an anti-CD40 monoclonal antibody (mAb)-based regimen. Ten life-supporting kidney transplants were carried out in baboons using α1,3-galactosyltransferase gene-knockout/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Eight transplants resulted in informative data. Immunosuppressive therapy consisted of induction with antithymocyte globulin and anti-CD20mAb, and maintenance based on either (1) CTLA4-Ig and/or tacrolimus (+rapamycin or mycophenolate mofetil) (GroupA [US Food and Drug Administration-approved regimens], n = 4) or (2) anti-CD40mAb + rapamycin (GroupB, n = 4). All baboons received corticosteroids, interleukin-6R blockade, and tumor necrosis factor-α blockade. Baboons were followed by clinical and laboratory monitoring of kidney function, coagulation, and immune parameters. At euthanasia, morphological and immunohistochemical studies were performed on the kidney grafts. The median survival in GroupB was 186 days (range 90-260), which was significantly longer than in GroupA; median 14 days (range 12-32) (P < 0.01). Only GroupA baboons developed consumptive coagulopathy and the histopathological features of thrombotic microangiopathic glomerulopathy and interstitial arterial vasculitis. Recognizing that the pig donors in each group differed in some genetic modifications, these data indicate that maintenance immunosuppression including anti-CD40mAb may be important to prevent pig kidney graft failure.

Sections du résumé

BACKGROUND
The aims of this study were to evaluate the efficacy of US Food and Drug Administration-approved drugs in genetically engineered pig-to-baboon kidney xenotransplantation and compare the results with those using an anti-CD40 monoclonal antibody (mAb)-based regimen.
METHODS
Ten life-supporting kidney transplants were carried out in baboons using α1,3-galactosyltransferase gene-knockout/CD46 pigs with various other genetic manipulations aimed at controlling coagulation dysregulation. Eight transplants resulted in informative data. Immunosuppressive therapy consisted of induction with antithymocyte globulin and anti-CD20mAb, and maintenance based on either (1) CTLA4-Ig and/or tacrolimus (+rapamycin or mycophenolate mofetil) (GroupA [US Food and Drug Administration-approved regimens], n = 4) or (2) anti-CD40mAb + rapamycin (GroupB, n = 4). All baboons received corticosteroids, interleukin-6R blockade, and tumor necrosis factor-α blockade. Baboons were followed by clinical and laboratory monitoring of kidney function, coagulation, and immune parameters. At euthanasia, morphological and immunohistochemical studies were performed on the kidney grafts.
RESULTS
The median survival in GroupB was 186 days (range 90-260), which was significantly longer than in GroupA; median 14 days (range 12-32) (P < 0.01). Only GroupA baboons developed consumptive coagulopathy and the histopathological features of thrombotic microangiopathic glomerulopathy and interstitial arterial vasculitis.
CONCLUSIONS
Recognizing that the pig donors in each group differed in some genetic modifications, these data indicate that maintenance immunosuppression including anti-CD40mAb may be important to prevent pig kidney graft failure.

Identifiants

pubmed: 31283686
doi: 10.1097/TP.0000000000002796
doi:

Substances chimiques

Antibodies, Monoclonal 0
CD40 Antigens 0
CD46 protein, human 0
Immunosuppressive Agents 0
Membrane Cofactor Protein 0
Galactosyltransferases EC 2.4.1.-
N-acetyllactosaminide alpha-1,3-galactosyltransferase EC 2.4.1.87

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2090-2104

Auteurs

Takayuki Yamamoto (T)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

Hidetaka Hara (H)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

Jeremy Foote (J)

Department of Microbiology and Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL.

Liaoran Wang (L)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.

Qi Li (Q)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.

Edwin C Klein (EC)

Division of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, PA.

Hendrik Jan Schuurman (HJ)

Schubiomed Consultancy, Utrecht, The Netherlands.

Hongmin Zhou (H)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
Department of Cardiothoracic Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Juan Li (J)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.
Second Affiliated Hospital, University of South China, Hengyang City, Hunan, China.

A Joseph Tector (AJ)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

Zhongqiang Zhang (Z)

Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.
Department of General Surgery and Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Mohamed Ezzelarab (M)

Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA.

Ray Lovingood (R)

Kirklin Clinic Pharmacy, University of Alabama at Birmingham, Birmingham, AL.

David Ayares (D)

Revivicor, Blacksburg, VA.

Devin E Eckhoff (DE)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

David K C Cooper (DKC)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

Hayato Iwase (H)

Xenotransplantation Program, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH